Sun.Jun 30, 2024

article thumbnail

Opinion: Congress called for an ALS moonshot. The plan for it doesn’t leave Earth

STAT

The National Academies of Sciences, Engineering, and Medicine recently released a congressionally mandated report on how to make amyotrophic lateral sclerosis — a brutal, always fatal condition — a “livable” disease in the next 10 years. Essentially, the committee was tasked with delivering a plan for a moonshot. As a health care innovation expert and someone living with ALS, I have to say that the report barely gets off the ground.

278
278
article thumbnail

NSAID Problems – Polypharmacy Case Study

Med Ed 101

With this med review, I’m simply looking at a medication list to help formulate ideas to investigate. I’ll focus heavily on my concern for using an NSAID in this patient. NSAID and Heart Failure Concerns There are a few issues of note with the cardiac/heart failure medication regimen. I always have the prescribing cascade in […] The post NSAID Problems – Polypharmacy Case Study appeared first on Med Ed 101.

105
105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Medicare’s big experiment to fix kidney failure care hasn’t worked so far, studies say

STAT

A few years ago, the Centers for Medicare and Medicaid Services launched a big experiment. The agency wanted to see if financial incentives and penalties would improve care for people with end-stage kidney disease. So far, it hasn’t worked, a new study finds. The End-Stage Renal Disease Treatment Choices (ETC) model is a historic effort, both because it’s the largest such experiment in the history of American health care and because, unlike previous CMS Innovation Center pilot prog

Hospitals 250
article thumbnail

First intranasal Epipen alternative backed in EU

pharmaphorum

After FDA rejection last year, ARS Pharma closes on EU approval for intranasal epinephrine product for anaphylaxis

69
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Which pharmaceutical companies have the most drug patents in Lithuania?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most patents in Lithuania. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.

article thumbnail

Skin On You – Market-Leading Aesthetics Pharmacy Website

pharmacy mentor

We can build anything at Pharmacy Mentor. We were very excited about the prospect of launching an aesthetics pharmacy clinic, which we knew would be a market-leading contender About This Pharmacy Skin On You is a B2B aesthetics pharmacy specialising in dermal filler products and delivering top-notch quality aesthetics products to practitioners at very competitive market prices.

More Trending

article thumbnail

Episode 935: What vasopressor is best to use in traumatic brain injury?

Pharmacy Joe

In this episode, I’ll discuss an article about which vasopressor is best in early traumatic brain injury patients. Episode 935: What vasopressor is best to use in traumatic brain injury? Subscribe on iTunes , Android , or Stitcher Patients who have severe traumatic brain injury and develop hypotension that requires vasopressor therapy are already at risk for mortality and poor long term outcomes.

article thumbnail

GEP ACQUIRES OPUSCAPITA

Pharma and Life Sciences Blog

GEP ACQUIRES OPUSCAPITA Vijendra Mon, 07/01/2024 - 09:43 Leading Europe-Based E-Invoicing Provider Expands GEP Leadership Across the Nordic Countries Learn More Asset type Newsroom Banner Slide Title GEP Acquires OpusCapita Mobile Banner Image Top Banner

52
article thumbnail

RAPS Convergence 2024 to Feature Session on Accelerating Breakthrough Device Commercialization — Led by HPM Medical Device Regulatory Expert Adrienne Lenz

FDA Law Blog: Biosimilars

RAPS Convergence 2024 is set to host a must-attend session on CDRH’s Total Product Life Cycle Advisory Program (TAP), promising attendees an exclusive insight into a pioneering initiative aimed at improving the medical device commercialization landscape. Session Details: A Path to Faster Breakthrough Device Commercialization – CDRH’s Total Product Life Cycle Advisory Program (TAP) Thursday, September 19, 2024, 4:30 PM – 5:30 PM Session Leader: Adrienne Lenz, RAC – Principal Medical Device Regula

52
article thumbnail

Redefining the Patient Experience: The Critical Role of Pharmacists and Patient Data in Addressing SDOH

Pharmacy Times

Pharmacists can also play a role in SDOH by replacing drug delivery with something else, such as food or transportation delivery, according to speakers at the ATOPP conference.

42
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

Asthma inhaler price cap in US may help pharma companies to secure more loyal customer base: GlobalData

Express Pharma

In the United States ( US), a recent initiative by major pharmaceutical companies to cap the cost of asthma inhalers at $35 per month marks a significant development in healthcare affordability and accessibility. Overall, the price cap on asthma inhalers represents a multifaceted victory. For patients, it means improved access to life-saving medications and a reduction in financial stress.